NovoCure Ltd 8-K

What Happened NovoCure Ltd (NASDAQ: NVCR) filed a Form 8-K on February 26, 2026 to announce its financial results for the fiscal year and quarter ended December 31, 2025. The company issued a press release with those results, which is attached to the filing as Exhibit 99.1 and is incorporated by reference into the 8-K. The report was signed by Chief Financial Officer Christoph Brackmann.

Key Details

• Filing date: February 26, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: fiscal year and quarter ended December 31, 2025 (Q4 2025 / FY2025 results announced).
• Press release attached as Exhibit 99.1 (incorporated by reference).
• Administrative exhibits included: Exhibit 104 (cover page interactive XBRL); filing signed by CFO Christoph Brackmann.

Why It Matters This 8-K notifies investors that NovoCure has published its FY2025 and Q4 2025 earnings and other financial metrics. The attached press release will contain the specific revenue, profit/loss, cash flow and management commentary investors use to assess company performance and near-term outlook. Investors should review Exhibit 99.1 for the detailed numbers and any forward-looking statements the company provides.